CJC-1295 (no DAC) CND
GHRH analogue
Modified GHRH(1-29) analogue studied for pulsatile growth hormone release through the pituitary GHRH receptor; shorter acting than the DAC form.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- GHRH analogue
- Category
- Growth Hormone Axis
- Type
- Single compound
- Abbreviation
- CND
- Development and regulatory status
- Not approved; investigational research compound
What researchers study
Modified 29-amino-acid analogue of growth hormone-releasing hormone (GHRH 1-29) with stabilising amino-acid substitutions. It binds the pituitary GHRH receptor and stimulates pulsatile growth hormone release, with a much shorter duration than the DAC-conjugated form.
Research areas
- Pituitary GH release and GHRH receptor signalling
- Pulsatile versus sustained GH secretion comparisons
- Combination studies with ghrelin-receptor agonists
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- review
A 2026 review lists CJC-1295 with and without DAC among unregulated GH-axis peptides lacking regulatory approval for performance indications
- human trial
For the DAC-conjugated form, trials in healthy adults found mean GH up 2- to 10-fold and IGF-I up 1.5- to 3-fold after a single administration
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Ipamorelinghrelin-receptor agonist acting on a separate pathway to GHRH analogues
- GHRP-2second ghrelin-receptor agonist studied alongside GHRH analogues
- Sermorelinrelated GHRH(1-29) analogue used as comparator in GHRH studies
- CJC-1295 (with DAC)albumin-binding counterpart used to contrast duration of action
